Table 6.
Treatment group | n | MADRS responder
|
MADRS remitter
|
||||
---|---|---|---|---|---|---|---|
Responders (%) | Difference (%) vs placebo | 95% CI for difference (%) | Remitters (%) | Difference (%) vs placebo | 95% CI for difference (%) | ||
Placebo | 186 | 86 (46.2) | – | – | 53 (28.5) | – | – |
BUP150 | 190 | 98 (51.6) | −5.3 | −15.4, 4.7 | 60 (31.6) | −3.1 | −12.3, 6.2 |
BUP300 | 188 | 82 (43.6) | 2.6 | −7.5, 12.7 | 56 (29.8) | −1.3 | −10.5, 7.9 |
Notes: An MADRS responder is defined as a subject with a ≥50% reduction from baseline in the MADRS total score at week 8. MADRS remitter is defined as a subject with ≤11 MADRS total score at week 8.
Abbreviations: BUP150, bupropion SR 150 mg/day (once daily); BUP300, bupropion SR 150 mg/day (twice daily); CI, confidence interval; ITT–LOCF, intent-to-treat, last observation carried forward; MADRS, Montgomery–Åsberg Depression Rating Scale; SR, sustained release; vs, versus; n, number.